Table 1.
Phase 1a | Phase 1b | |
---|---|---|
Cancer site | ||
Bladder | 7 | 32 |
Breast | 17 | 53 |
Colorectal | 12 | 46 |
Glioma | 10 | 36 |
Gynecological | 12 | 49 |
Head & neck | 10 | 44 |
Lung | 8 | 41 |
Lymphoma | 9 | 38 |
Melanoma | 11 | 38 |
Prostate | 11 | 44 |
Testicular | 10 | 37 |
Total | 117 | 458 |
Region | ||
Northern Europe | 30 | 147 |
Southern Europe | 46 | 126 |
English speaking | 13 | 98 |
Central Europe | 28 | 87 |
Time since diagnosis | ||
0.5 to 2 years | 21 | 111 |
2 to 5 years | 63 | 189 |
more than 5 years | 33 | 158 |
Time since completing last treatmenta | ||
0.5 to 1 year | – | 72 |
1 to 2 years | – | 105 |
2 to 5 years | – | 172 |
more than 5 years | – | 109 |
For phase 1b only, also the number of survivors per time since completion of last treatment category is reported
aFor phase 1a only information was available regarding date of diagnosis and date of recurrence